Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 October 2018Website:
http://kodiak.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:02:56 GMTDividend
Analysts recommendations
Institutional Ownership
KOD Latest News
PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois.
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 6, 2024, 8:00 AM ET (5:00 AM PT), New York, New York Goldman Sachs 45th Annual Global Healthcare Conference, June 13, 2024, 8:00 AM ET (5:00 AM PT), Miami Beach, Florida A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
Kodiak (KOD) announces strong first-quarter 2024 results and shares progress on its pipeline development strategies.
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
- 1(current)
What type of business is Kodiak Sciences?
Kodiak Sciences Inc. is an independent biopharmaceutical company engaged in research, development, and commercialization of innovative biopharmaceutical drugs for the treatment of common eye diseases. Founded in June 2009, it is headquartered in Palo Alto, California. Kodiak Sciences Inc. does not have any developed drugs approved for commercial sale, and the company does not generate revenue from their sale. The company does not expect to generate revenue from sales until it completes development and clinical trials and receives regulatory approval for commercial sale of the developed drugs.
What sector is Kodiak Sciences in?
Kodiak Sciences is in the Healthcare sector
What industry is Kodiak Sciences in?
Kodiak Sciences is in the Biotechnology industry
What country is Kodiak Sciences from?
Kodiak Sciences is headquartered in United States
When did Kodiak Sciences go public?
Kodiak Sciences initial public offering (IPO) was on 04 October 2018
What is Kodiak Sciences website?
https://kodiak.com
Is Kodiak Sciences in the S&P 500?
No, Kodiak Sciences is not included in the S&P 500 index
Is Kodiak Sciences in the NASDAQ 100?
No, Kodiak Sciences is not included in the NASDAQ 100 index
Is Kodiak Sciences in the Dow Jones?
No, Kodiak Sciences is not included in the Dow Jones index
When was Kodiak Sciences the previous earnings report?
No data
When does Kodiak Sciences earnings report?
The next expected earnings date for Kodiak Sciences is 14 November 2024